Optimeos Life Sciences

Therapeutic RNAs are becoming one of the dominant modalities to treat disease in the near future. Yet, while the industry has made rapid strides in engineering RNA payloads to be more tolerable, effective and long-lasting, RNA delivery still relies on the first generation of lipid nanoparticle technology.

Optimeos has developed a novel nanoparticle platform to deliver the potential of RNA and DNA medicines across the range of human disease.

‍